Latest News on NVAX

Financial News Based On Company


Advertisement
Advertisement

Sunrun, PacBio, and Novavax stocks trade down, what you need to know

https://www.tradingview.com/news/stockstory:df5ce5890094b:0-sunrun-pacbio-and-novavax-stocks-trade-down-what-you-need-to-know/
Shares of renewable energy company Sunrun, genomics firm PacBio, and therapeutics company Novavax all experienced declines after news of leadership uncertainty at Nvidia and the resignation of CEO Jensen Huang. The market reaction to Nvidia's executive transition triggered a broader sell-off in technology and AI-related shares, prompting investors to reassess growth trajectories. Novavax, despite its recent volatility and year-to-date gains, saw a 6% drop, though the company recently raised its full-year 2026 revenue outlook.

Novavax to Participate in Jefferies London Healthcare Conference

https://www.quantisnow.com/insight/novavax-to-participate-in-jefferies-london-healthcare-conference-6785522
Novavax announced its management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at 5:00 p.m. GMT. A live webcast will be available on the company's website, with a replay accessible for 30 days. This is a scheduled investor event and does not contain new financial or clinical information.

Novavax Inc. stock underperforms Wednesday when compared to competitors

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-wednesday-when-compared-to-competitors-c6ac3231-9cc930470b9c?mod=goog_fin_scmw
Novavax Inc. (NVAX) shares fell 2.16% to $9.98 on Wednesday, despite an overall positive trading session for the broader stock market. This marked the second consecutive day of losses for the stock. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains, rising 1.60% and 0.49% respectively.

A passive holder reports 8.83 million shares in Novavax (NVAX).

https://www.stocktitan.net/sec-filings/NVAX/schedule-13g-novavax-inc-passive-investment-disclosure-5-6433a065a8fb.html
State Street Corporation has reported a passive stake in Novavax (NVAX), holding 8,827,707 shares of common stock, which represents 5.4% of the class, as of September 30, 2026. The filing indicates shared voting power over 8,362,217 shares and shared dispositive power over 8,827,707 shares, with no sole voting or dispositive power. This disclosure was made via a SCHEDULE 13G filing with the SEC.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

https://sg.finance.yahoo.com/news/novavax-inc-nvax-trending-stock-130006465.html
Novavax (NVAX) is a trending stock due to recent investor interest, despite a -14% return over the past month. Zacks Equity Research provides insights into the company's earnings estimates, revenue growth, and valuation to help investors make informed decisions, noting its Zacks Rank #3 (Hold) suggests it may perform in line with the broader market.
Advertisement

NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook

https://ca.finance.yahoo.com/news/nvax-q3-2026-deep-dive-130136291.html
Novavax reported better-than-expected revenue and adjusted EPS in Q3 2026, primarily due to a $125 million milestone payment from Sanofi for its combination vaccine trial. Despite a year-over-year sales decline, the company highlighted significant cost reductions and ongoing efforts to expand its Matrix-M adjuvant platform and pipeline. Management anticipates future performance will rely on continued partner milestones and further expense controls to achieve non-GAAP profitability by 2029.

Novavax, Inc. (NVAX) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/NVAX/seasonality/
The article provides a chart for Novavax, Inc. (NVAX) seasonal returns but indicates that seasonality data is currently unavailable for the stock. It shows the current stock price and daily change.

Novavax (NVAX) stock trades up, here is why

https://www.theglobeandmail.com/investing/markets/stocks/NVAX/pressreleases/8706792/novavax-nvax-stock-trades-up-here-is-why/
Shares of Novavax (NVAX) jumped 8.8% after the company reported strong third-quarter 2026 financial results, raising its full-year adjusted total revenue outlook to a $400 million mid-point. Additionally, Novavax received a $125 million milestone payment as Sanofi initiated a Phase 3 combination vaccine trial. The company also significantly reduced its net loss compared to the previous year.

Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Novavax (NVAX)

https://www.theglobeandmail.com/investing/markets/stocks/NVAX/pressreleases/8716438/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-novavax-nvax/
Analysts have provided new ratings on Incyte (INCY) and Novavax (NVAX) in the Healthcare sector. H.C. Wainwright maintained a Buy rating on Incyte with a $152.00 price target, while Bank of America Securities reiterated a Sell rating on Novavax with a $7.00 price target. The article details analyst consensus and price targets for both companies.

Novavax (NVAX) stock trades up, here is why

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-6-novavax-nvax-stock-trades-up-here-is-why
Shares of Novavax (NVAX) jumped 8.8% after the company reported improved third-quarter 2026 financial results, raising its full-year adjusted total revenue outlook to a $400 million mid-point. Additionally, Novavax received a $125 million milestone payment as Sanofi initiated a Phase 3 combination vaccine trial. The market perceived this news as meaningful, coming after a period of volatility and recent gains due to easing regulatory uncertainty in the biopharmaceutical sector following election results.
Advertisement

Novavax Raises 2026 Revenue Outlook to $400 Million as Sanofi Vaccine Partnership Advances

https://www.citybiz.co/article/930314/novavax-raises-2026-revenue-outlook-to-400-million-as-sanofi-vaccine-partnership-advances/
Novavax (NASDAQ: NVAX) has significantly raised its 2026 revenue outlook to a midpoint of $400 million, an increase of $145 million, driven by a major milestone in its partnership with Sanofi. This revised forecast follows Sanofi's initiation of a Phase III clinical trial for a combination influenza and COVID-19 vaccine, triggering a $125 million milestone payment to Novavax. The company also reported a sharply narrower third-quarter loss and is implementing a restructuring strategy to extend its financial runway into 2029 by cutting operating costs and focusing on licensing.

Form 8K Novavax Inc For: 5 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-novavax-inc-for-5-november-93CH-4934718
This article announces that Novavax Inc. has filed a Form 8K for November 5th. The filing is a standard regulatory disclosure and provides no further details within this brief report from Investing.com. It is solely an informational notice about the company's SEC filing.

Form 10-Q NOVAVAX INC For: Sep 30

https://www.streetinsider.com/SEC+Filings/Form+10-Q+NOVAVAX+INC+For%3A+Sep+30/27295667.html
Novavax, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, reporting a net loss of $94.3 million for the nine months ended September 30, 2026, compared to a net income of $422.8 million for the same period in 2025. The company's revenue decreased significantly due to non-recurring product sales from APA terminations in 2025 and lower licensing and royalty revenue, partially offset by new agreements with Pfizer and Sanofi. Novavax also highlighted its ongoing restructuring efforts and commitment to strategic partnerships for its Matrix-M® adjuvant and vaccine candidates.

Novavax boosts 2026 revenue forecast as licensing deals pay off

https://wtvbam.com/2026/11/05/novavax-boosts-2026-revenue-forecast-as-licensing-deals-pay-off/
Novavax has raised its 2026 adjusted revenue forecast above Wall Street expectations, attributing the increase to successful licensing deals and partnerships. The vaccine maker's shares rose over 3% in premarket trading following the announcement. The company aims to achieve profitability by 2028, largely supported by a significant licensing agreement with Sanofi.

NOVAVAX ($NVAX) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/NOVAVAX+%28%24NVAX%29+Releases+Q3+2026+Earnings
NOVAVAX ($NVAX) announced its Q3 2026 earnings, reporting -$0.19 per share, which beat analyst estimates of -$0.34. The company's revenue reached $68,300,000, also surpassing estimates by over $16 million. Institutional investor activity showed a mixed sentiment, with 106 firms increasing and 124 decreasing their positions in NOVAVAX stock.
Advertisement

Novavax: Q3 Earnings Snapshot

https://sg.finance.yahoo.com/news/novavax-q3-earnings-snapshot-130714240.html
Novavax Inc. reported a third-quarter loss of $31.4 million, or 19 cents per share, which was better than Wall Street's expectation of a 37-cent loss per share. The vaccine maker also posted revenue of $68.3 million for the period.

Loss narrows to $31.4M as Novavax (NVAX) raises its 2026 adjusted revenue outlook.

https://www.stocktitan.net/sec-filings/NVAX/8-k-novavax-inc-reports-material-event-468123f1e591.html
Novavax reported a narrowed net loss of $31.376 million in Q3 2026, significantly down from $202.379 million a year earlier, and raised its full-year 2026 Adjusted Total Revenue framework to $385 million–$415 million. This increase is partly due to a $125 million milestone earned from Sanofi for initiating a Phase 3 influenza-COVID-19 trial in Europe, with potential for further milestone payments tied to U.S. launch and technology transfer. The company also improved its GAAP combined R&D and SG&A expense guidance and anticipates its C. difficile vaccine program to advance into clinics by 2027.

Novavax Beats On A Narrower Loss And Lifts Its Outlook On Sanofi's $125 Million Milestone, But Its Profitability Target Slides To 2029

https://finviz.com/news/417361/novavax-beats-on-a-narrower-loss-and-lifts-its-outlook-on-sanofis-125-million-milestone-but-its-profitability-target-slides-to-2029
Novavax (NVAX) reported a narrower-than-expected third-quarter loss and raised its full-year adjusted revenue outlook, primarily due to a $125 million milestone payment from Sanofi for initiating a Phase 3 influenza-COVID combination trial. Despite the beat, the company's path to profitability has been pushed back to 2029, coinciding with a planned U.S. launch of the combination vaccine, and some improvements in the quarter were attributed to non-recurring events and non-cash revenue. The article highlights both the legitimate concerns for bears regarding dwindling legacy income and the positive developments such as strong Nuvaxovid demand, extended cash runway, and deeper cost cuts.

Novavax, Inc. (NVV1.F) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/NVV1.F/seasonality/
This Yahoo Finance page provides a seasonal returns chart for Novavax, Inc. (NVV1.F), displaying the average monthly price return from 2016 to 2026. The page also includes current stock performance, market data, and information about the upcoming Q3 2026 earnings call.

Novavax (NVAX) reports earnings tomorrow: what to expect

https://www.tradingview.com/news/stockstory:83cdbf830094b:0-novavax-nvax-reports-earnings-tomorrow-what-to-expect/
Novavax (NVAX) is set to report earnings before market hours on Thursday. The company beat revenue and EPS expectations last quarter, but analysts anticipate a revenue decline of 36.4% year-on-year for the upcoming report. Despite positive sentiment in the broader therapeutics segment, Novavax's stock is down 23.2% over the last month, trading below its average analyst price target.
Advertisement

Novavax, Inc. (NVAX.MX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/NVAX.MX/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Novavax, Inc. (NVAX.MX). It shows the average monthly price return for the company from 2020 to 2026. The page also includes current stock information, related tickers, and upcoming earnings call details.

Novavax Inc. stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-monday-when-compared-to-competitors-46be52ca-53fdcc415eec
Novavax Inc. (NVAX) shares fell 5.46% on Monday, closing at $9.53. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the NASDAQ Composite Index falling. The stock experienced its second consecutive day of losses.

Novavax trials COVID-19 vaccine in South Africa

https://www.reuters.com/video/watch/idOVCRN8T4B/
US drug developer Novavax Inc has begun a mid-stage study of its experimental COVID-19 vaccine in South Africa, a country facing a surge in coronavirus cases. The trial will assess the vaccine's safety and immunogenicity in approximately 2,665 healthy adults and 240 HIV-positive adults. The Bill and Melinda Gates Foundation is contributing a $15 million grant to support the clinical trial.

Novavax, Inc. (NVAX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/NVAX/seasonality/
This article from Yahoo Finance displays the historical seasonality of Novavax, Inc. (NVAX) stock, showing its average monthly price returns from 2016 to 2026. The current stock price for Novavax is reported at 9.77 USD, reflecting a -3.08% change. The page also provides links to various financial data and analysis for NVAX.

Novavax Inc. stock underperforms Thursday when compared to competitors despite daily gains

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-thursday-when-compared-to-competitors-despite-daily-gains-e29883f7-05b703380c54?mod=mw_quote_news
Novavax Inc. (NVAX) stock rallied 1.45% on Thursday to close at $10.47, despite a generally negative trading session for the broader market. The NASDAQ Composite Index (COMP) fell 1.38%, and the Dow Jones Industrial Average (DJIA) fell 0.25%. This marked the stock's third consecutive day of gains, yet it still underperformed some competitors.
Advertisement

Novavax earns $125M milestone from Sanofi vaccine trial

https://www.investing.com/news/company-news/novavax-earns-125m-milestone-from-sanofi-vaccine-trial-93CH-4984063
Novavax (NASDAQ:NVAX) has received a $125 million milestone payment from Sanofi after the initiation of Sanofi’s Phase 3 trial for an influenza-COVID-19 combination vaccine. This trial integrates Novavax’s Nuvaxovid vaccine and evaluates its safety and immunogenicity in adults aged 60 and older. The partnership has already generated over $1 billion in revenue for Novavax, with potential for additional milestone payments and royalties.

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

https://www.prnewswire.com/news-releases/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combination-vaccine-trial-in-europe-302923786.html
Novavax has received a $125 million milestone payment as its partner, Sanofi, initiated a Phase 3 clinical trial in Europe for an influenza-COVID-19 combination vaccine. This trial uses Novavax's Nuvaxovid™ COVID-19 vaccine combined with Sanofi's Efluelda/Fluzone® High-Dose flu vaccine in adults aged 60 and older. The partnership has generated over $1 billion for Novavax, with potential for additional milestones and royalties, including $225 million upon a successful U.S. launch of the combination vaccine.

A flu-COVID vaccine trial in people 60 and older brings Novavax $125 million

https://www.stocktitan.net/news/NVAX/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-f0m6r5tzfi5b.html
Novavax (Nasdaq: NVAX) has received a $125 million milestone payment as Sanofi began a Phase 3 clinical trial in Europe for its influenza-COVID-19 combination vaccine. The trial, assessing safety and immune responses in adults aged 60 and older, combines Novavax's Nuvaxovid with Sanofi's Efluelda/Fluzone High-Dose flu vaccine. This partnership has already generated over $1 billion in revenue for Novavax, with potential for an additional $75 million for technology transfer and $225 million for a U.S. launch.

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

https://finance.yahoo.com/healthcare/articles/novavax-report-third-quarter-2026-120000789.html
Novavax, Inc. announced its plan to release third-quarter 2026 financial results on November 5, 2026, before the U.S. financial markets open. Following the release, company management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and operational highlights. Details for joining the call and webcast, along with replay information, have been provided.

Cantor Fitzgerald sets USD 18 target for Novavax stock

https://www.ad-hoc-news.de/boerse/news/corporate-news/cantor-fitzgerald-sets-usd-18-target-for-novavax-stock/70423206
Cantor Fitzgerald has initiated coverage on Novavax (NVAX) with a Buy rating and a USD 18.00 price target, significantly higher than its current trading price. The company reported second-quarter 2026 revenue of USD 57.00 million, down from USD 239.00 million year-over-year, but expects full-year 2026 revenue between USD 235.00 million and USD 275.00 million. Novavax is set to release its third-quarter 2026 results on November 5, 2026, which will be critical given the divided market view among analysts.
Advertisement

Novavax Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-0520aef0-23fb0d2fa6d7?mod=mw_quote_news
Shares of Novavax Inc. (NVAX) surged 6.60% to $10.02 on Tuesday, outperforming the broader market which also saw gains in the NASDAQ Composite and Dow Jones Industrial Average. This increase ended a four-day losing streak for the stock.

Novavax, Inc. (NVAX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/NVAX/latest-news/
This Yahoo Finance page provides current stock information for Novavax, Inc. (NVAX), including its real-time price, recent news headlines, and market performance. The stock is currently trading at $10.25, up 2.24% as of 11:22:34 a.m. EDT. Recent news covers market analyses, investor insights, and reports on a shareholder stepping back from an activist role.

Novavax, Inc. (NVAX) Company Profile & Facts

https://ca.finance.yahoo.com/quote/NVAX/profile/
This article provides a detailed company profile for Novavax, Inc. (NVAX), a biotechnology company focused on vaccine development. It includes key executive compensation, company contact information, sector and industry details, a business description, and corporate governance scores. The profile also lists upcoming and recent corporate events.

Novavax, Inc. Estimates – NASDAQ:NVAX

https://www.tradingview.com/symbols/NASDAQ-NVAX/financials-estimates/
This page provides financial actuals and analyst estimates for Novavax, Inc. (NASDAQ: NVAX), including data for the income statement, balance sheet, cash flow statement, and various valuation metrics. Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time for both annual and quarterly periods. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.

Novavax Inc. stock underperforms Friday when compared to competitors

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-friday-when-compared-to-competitors-024d6ae9-07bf6eb3ccc4
Novavax Inc. (NVAX) shares fell 2.90% on Friday, closing at $9.70, underperforming the broader market. The NASDAQ Composite Index dropped 0.21%, and the Dow Jones Industrial Average declined 1.23%. This marks the third consecutive day of losses for Novavax stock.
Advertisement

Novavax Shareholder Himanshu Shah To Focus On Family Office

https://indiawest.com/novavax-shareholder-himanshu-shah-to-focus-on-family-office/
Shah Capital, formerly a significant activist investor and the second-largest shareholder in Novavax, Inc., has announced its transition into a family office. Founder Himanshu Shah will now oversee investment operations under the Himanshu Shah Family Office LLC, shifting the firm's SEC reporting status for Novavax shares from active to passive. Despite a partial stake reduction, Shah Capital and Himanshu Shah still hold a substantial ownership position in Novavax.

Novavax, Inc. (NVAX) latest stock news and headlines – Yahoo Finance

https://sg.finance.yahoo.com/quote/NVAX/news/
This article provides a compilation of recent news headlines related to Novavax, Inc. (NVAX) stock performance and associated market movements. It features several links to articles from sources like Simply Wall St., Zacks, Reuters, Barrons.com, and Yahoo Finance, covering topics such as stock valuation, analyst opinions, market performance, and corporate actions like Shah Capital stepping back from an activist role. The news spans a period of about two weeks, highlighting various factors influencing NVAX.

Novavax Inc (NVAX) News, Articles, Events & Latest Updates

https://stocktwits.com/symbol/NVAX/news
This article provides a compilation of recent news and updates concerning Novavax Inc. (NVAX), highlighting its stock performance and investor interest. Several reports from Zacks analyze NVAX's movements relative to market trends, while other articles discuss a rally in vaccine stocks, including Novavax, driven by news of a U.S.-led initiative for cancer vaccines and anxiety stirred by suspected pneumonic plague.

Novavax Inc Lobbying Profile, 2014

https://www.opensecrets.org/federal-lobbying/clients/novavax-inc?client_id=187601&cycle=2014
This page from OpenSecrets.org provides a lobbying profile for Novavax Inc, a pharmaceutical/health products company, detailing its federal lobbying activities for 2026. As of July 23, 2026, Novavax Inc had spent $270K on direct lobbying, with no spending through subsidiaries. The profile includes sections like a summary, hired firms, lobbyists, issues, agencies, bills, and report images.

Novavax Inc. stock underperforms Thursday when compared to competitors

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-thursday-when-compared-to-competitors-754a5a7f-04b5e306729d
Novavax Inc. (NVAX) shares fell by 9.26% on Thursday, closing at $9.99. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the NASDAQ Composite Index declined. This marks the second consecutive day of losses for Novavax stock.
Advertisement

Novavax, Inc. (NVAX) interactive stock chart – Yahoo Finance

https://sg.finance.yahoo.com/quote/NVAX/chart/
This page provides an interactive stock chart for Novavax, Inc. (NVAX) on Yahoo Finance. It displays real-time stock prices, pre-market activity, and a summary of recent news relevant to the company and the broader vaccine market. The article highlights NVAX's current trading figures and links to various news articles from sources like Zacks, Reuters, and Barrons.com.

Novavax, Inc. (NVAX) latest stock news and headlines

https://uk.finance.yahoo.com/quote/NVAX/news/
This article compiles recent news and headlines related to Novavax, Inc. (NVAX), covering its stock performance and various analyst opinions. Topics range from its current stock valuation and risk factors to its involvement in vaccine efforts and reactions to market trends like the "Russian Plague Scare." The article also includes a performance overview comparing NVAX's returns to the S&P 500 benchmark.

Working capital per share of Novavax, Inc. – XETR:NVV1

https://www.tradingview.com/symbols/XETR-NVV1/financials-statistics-and-ratios/working-capital-per-share/
This article provides data on the working capital per share of Novavax, Inc. (XETR:NVV1). It appears to be a financial data point from TradingView, indicating no current trades and a closed market for the stock. The content is brief, focusing solely on this specific financial metric.

Novavax Inc. stock underperforms Wednesday when compared to competitors

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-wednesday-when-compared-to-competitors-ec430bc5-6dfebff4980a?mod=mw_quote_news
Novavax Inc. (NVAX) shares fell 3.67% to $11.01 on Wednesday, despite an overall favorable trading session for the broader stock market, with both the NASDAQ Composite and Dow Jones Industrial Average posting gains. The company's stock closed 17.74% below its 52-week high reached earlier in October.

Novavax Inc (Coinbase Tokenized Stock) (NVAXC) Price Prediction for 2026 to 2031

https://www.bybit.com/en/price-prediction/novavax-inc-coinbase-tokenized-stock/
This article provides price predictions for Novavax Inc (Coinbase Tokenized Stock) (NVAXC) from 2026 to 2045, based on Bybit AI's analysis of user-driven Consensus Ratings and historical patterns. It forecasts a positive trend and growth for NVAXC, with expected prices increasing significantly over the years. The piece also includes a disclaimer about the inherent market risks associated with cryptocurrency investments.
Advertisement

Novavax, Inc. (NVAX) latest stock news and headlines

https://au.finance.yahoo.com/quote/NVAX/news/
This article provides a compilation of recent news and headlines concerning Novavax, Inc. (NVAX), including its stock performance and related market news. It highlights various factors influencing NVAX's stock movement, such as market improvements, vaccine developments, and reactions to health scares. The article also includes a performance overview comparing NVAX's trailing total returns against the S&P 500.

Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push

https://www.benzinga.com/news/health-care/26/10/62436713/novavaxs-second-largest-shareholder-sells-32-6-million-in-stock-ends-activist-push
Shah Capital, previously Novavax's second-largest shareholder, sold 2.87 million shares worth $32.6 million and is discontinuing its activist investor role to become a family office. The firm had previously pushed for Novavax to consider a sale and opposed its board nominees, citing poor performance. Despite the sale, Himanshu Shah still beneficially owns 6.46% of Novavax's shares.

Novavax Inc Tokenized Stock (Coinbase) Price History and Historical Data

https://coinmarketcap.com/currencies/novavax-inc-tokenized-stock-coinbase/historical-data/
This article provides the title for the Novavax Inc Tokenized Stock (Coinbase) Price History and Historical Data page on CoinMarketCap. It appears to be a stub or a placeholder, as it primarily consists of navigation links and various product/resource categories offered by CoinMarketCap, without actual historical data for the tokenized stock.

Novavax Inc (Coinbase Tokenized Stock) to Russian Ruble Price Today | Live NVAXc to RUB Converter & Exchange Rate | CryptoRank.io

https://cryptorank.io/price/novavax-inc-coinbase-tokenized-stock/rub
This article provides details on the Novavax Inc (Coinbase Tokenized Stock) (NVAXc) to Russian Ruble (RUB) exchange rate, noting that there is currently no available exchange rate due to inactivity or very low trading volume. It includes a 7-day price history showing a consistent value of ₽6.57K, and answers frequently asked questions regarding its price and conversion. The platform tracks market performance, fundraising, exchanges, token unlocks, and offers various analytical tools for cryptocurrencies.

Novavax shareholder Shah Capital to step back from activist role

https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-shareholder-shah-capital-step-back-activist-role-2026-10-16/
Shah Capital, a major shareholder in Novavax, announced its decision to cease its activist role in the vaccine maker after restructuring into a family office. The firm has filed with the US SEC to withdraw its registration as an investment adviser, with Himanshu Shah Family Office LLC taking over investment management. Shah Capital also disclosed selling 2.87 million Novavax shares on October 5.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement